Evidence map›Paper›PMID 37819378›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2023

Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome.

Ana Ricobaraza, Maria Bunuales, Manuela Gonzalez-Aparicio, Saja Fadila, Moran Rubinstein, Irene Vides-Urrestarazu, Julliana Banderas, Noemi Sola-Sevilla, Rocio Sanchez-Carpintero, Jose Luis Lanciego and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Genetic medicines for epilepsy: unlocking new avenues for seizure control.Frontiers in bioengineering and biotechnology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. State-of-the-art gene therapy in epilepsy.Current opinion in neurology · 2025
    Review
  6. Dravet syndrome: novel insights intoFrontiers in neuroscience · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Ana RicobarazaGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Maria BunualesGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Manuela Gonzalez-AparicioGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Saja FadilaSackler Faculty of Medicine, Goldschleger Eye Research Institute, Tel Aviv University, Tel Aviv, Israel.
Moran RubinsteinSackler Faculty of Medicine, Goldschleger Eye Research Institute, Tel Aviv University, Tel Aviv, Israel.
Irene Vides-UrrestarazuGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Julliana BanderasGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Noemi Sola-SevillaGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain.
Rocio Sanchez-CarpinteroUniversity Clinic of Navarra, Dravet Syndrome Unit, Pediatric Neurology Unit, IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Jose Luis LanciegoDepartment of Neuroscience, CIMA, University of Navarra, Pamplona, Spain.
Elvira RodaDepartment of Neuroscience, CIMA, University of Navarra, Pamplona, Spain.
Adriana HonrubiaDepartment of Neuroscience, CIMA, University of Navarra, Pamplona, Spain.
Patricia ArnaizDepartment of Neuroscience, CIMA, University of Navarra, Pamplona, Spain.
Ruben Hernandez-AlcocebaGene Therapy and Regulation of Gene Expression Program, CIMA, University of Navarra, CIMA, Av. Pio XII 55, E-31008, Pamplona, Spain. rubenh@unav.es.ORCID 0000-0002-6682-2598
Universidad de Navarra · ESTel Aviv University · ILBiomedical Research Networking Center on Neurodegenerative Diseases · ES

Funding

Fundacion Sindrome de Dravet FSD2020-XI-IInstituto de Salud Carlos III TERAV/ISCIII Next Generation EU-PRTR RD21/0017/0034Israel Science Foundation 1454/17Israel Science Foundation 214/22Ministerio de Ciencia e Innovación RTI2018-097730-B-I00/MCI/AEI/FEDER
6 · The paper itself

Abstract

The SCN1A gene encodes the alpha subunit of a voltage-gated sodium channel (Na

Indexed as

Epilepsies, MyoclonicNAV1.1 Voltage-Gated Sodium ChannelAnimalsDisease Models, AnimalDNA, ComplementaryGABAergic NeuronsMicePhenotypeDNA, ComplementaryNAV1.1 Voltage-Gated Sodium ChannelScn1a protein, mouseAdenoviral vectorDlxDP3VDravet syndromeEpileptic encephalopathyErbB4GABAergic neuronNav1.1SCN1A

Identifiers

PMID37819378
PMCPMC10697872
OpenAlexW4387527603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.